| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on ,
Accepted on ,
Technical Briefs |
1 Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany
2 Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany
* To whom correspondence should be addressed. E-mail: M.Weber{at}kerckhoff-klinik.de.
Background: Several studies have consistently shown that soluble CD40 ligand (sCD40L) concentrations are increased in patients with acute coronary syndromes and can serve as a biomarker for risk stratification. However, few data are available on preanalytic conditions that impact sCD40L values. Thus, the aim of our prospective study was to evaluate the impact of sampling techniques and storage conditions on sCD40L concentrations.
Methods: We included a total of 30 patients with no, stable, or unstable coronary heart disease. Blood samples were collected in gel-filled tubes without additives, in EDTA-filled tubes, and in citrate-filled tubes and were kept at various storage conditions.
Results: Median (interquartile range) sCD40L values at baseline were higher in serum samples [5.29 (3.89-6.33) µg/L] than in either EDTA plasma [0.78 (0.39-1.12) µg/L; P <0.001] or citrate plasma [0.37 (0.22-0.51) µg/L; P <0.001]. Serum values increased with delayed processing [7.94 (5.97-9.62) µg/L after 1.5 h (P <0.001) vs baseline; 10.55 (7.58-11.55) µg/L after 3 h (P <0.001) vs baseline]. However, after centrifugation, sCD40L values remained stable for all 3 sample types.
Conclusion: Plasma, but not serum, samples are appropriate for sCD40L measurements. In general, preanalytic conditions are critical in the assessment of sCD40L concentrations and thus should be carefully considered for future studies.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  F. S. Apple, S. W. Smith, L. A. Pearce, and M. M. Murakami Assessment of the Multiple-Biomarker Approach for Diagnosis of Myocardial Infarction in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., January 1, 2009; 55(1): 93 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Plaikner, A. Peer, G. Falkensammer, C. Schmidauer, C. Pechlaner, A. Griesmacher, O. Pachinger, and J. Mair Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department Clin. Chem., January 1, 2009; 55(1): 175 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18 Eur. Heart J., May 1, 2008; 29(9): 1096 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weber and C. Hamm Novel biomarkers--the long march from bench to bedside Eur. Heart J., May 1, 2008; 29(9): 1079 - 1081. [Full Text] [PDF]
|
|
|
|
|
|
R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Ivandic, E. Spanuth, D. Haase, H.-G. Lestin, and H. A. Katus Increased Plasma Concentrations of Soluble CD40 Ligand in Acute Coronary Syndrome Depend on in Vitro Platelet Activation Clin. Chem., July 1, 2007; 53(7): 1231 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, L. A. Pearce, A. Chung, R. Ler, and M. M. Murakami Multiple Biomarker Use for Detection of Adverse Events in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., May 1, 2007; 53(5): 874 - 881. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
